Raffaele Califano, Professor of Medical Oncology at the University of Manchester, posted on LinkedIn:
“The Lung Team at the Christie is currently recruiting patients in a study using olomorasib in combination with pembrolizumab with or without chemotherapy for first-line treatment of patients with advanced NSCLC (non-small cell lung cancer) harbouring a KRAS G12C mutation please contact [email protected] for more information.”
More posts featuring Raffaele Califano on OncoDaily.